cancer

IRP’s Jennifer Webster-Cyriaque Elected to the National Academy of Medicine

NIH Scientist Proves What Happens in the Mouth Doesn’t Stay in the Mouth

Dr. Jennifer Webster-Cyriaque

For many people, good oral health means a pretty smile, not necessarily a healthy body. However, poor dental health can lead to serious illness and disability. IRP senior investigator Jennifer Webster-Cyriaque, D.D.S., Ph.D., has spent her career illuminating the connection between our mouths and our overall health. Dr. Webster-Cyriaque, who recently joined NIH as Deputy Director of the National Institute of Dental and Craniofacial Research (NIDCR) and Chief of the Viral Oral Infections in Immunosuppression and Cancer Laboratory at the National Institute of Allergy and Infectious Diseases (NIAID), was elected to the National Academy of Medicine in October for her seminal contributions to our understanding of viruses that infect the mouth.

Poster Session Showcases IRP Graduate Students

Event Includes In-Person Presentations for First Time Since 2020

people looking at posters at the 2023 NIH Graduate Student Research Symposium poster session

Three years after COVID-19 dramatically changed the way scientists and many others work, much of life in the NIH IRP has begun to resemble the way things were in February of 2020. This includes the return of in-person scientific poster sessions like the one that took place on February 16 as part of the 19th annual NIH Graduate Student Research Symposium. Nearly 130 graduate students conducting their Ph.D. research in IRP labs as part of NIH’s Graduate Partnership Program presented their progress at that poster session and its virtual counterpart held February 15.

The two poster sessions made it clear that IRP graduate students are essential contributors to the life-changing discoveries made at NIH, from using geckos to learn about human eye diseases to investigating how the immune system combats infectious invaders to exploring ways to improve cancer treatment. Keep reading to learn about some of the bright scientists-in-training who showed off their work during the two-day event.

NIH Mourns Two Accomplished Cancer Researchers

A Tribute to Drs. James M. Phang and John J. DiGiovanna

Dr. John J. DiGiovanna (left) and Dr. James M. Phang (right)

The IRP is deeply saddened by the recent passing of two members of its community, James "Jim" M. Phang, M.D., and John J. DiGiovanna, M.D. Dr. Phang passed away on January 29 after a months-long struggle with esophageal cancer. Dr. DiGiovanna died on February 6, more than two years after his diagnosis of metastatic pancreatic cancer.

Creating Cutting-Edge Cancer Vaccines

IRP Research Identifies a Tantalizing Target for Cancer Immunotherapy

person getting vaccine injection

February 4 is World Cancer Day, a time to mark international efforts to prevent, detect, and treat cancer. Immunotherapy, one of the most significant advances in treating cancer, was pioneered here at NIH more than 30 years ago. Today, IRP senior investigator Claudia M. Palena, Ph.D., is pushing cancer immunotherapy forward with the discovery of a novel target for cancer vaccines.

IRP’s Bruce Tromberg Elected to National Academy of Medicine

Advances in Bioengineering Drive Life-Saving Medicine

Dr. Bruce Tromberg

“To discover new things, you need new ways to see them,” says Bruce J. Tromberg, Ph.D., Director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB). That’s why he has spent the past 30 years of his career improving and inventing tools to help doctors and scientists conduct cutting-edge biomedical research and apply their findings to the task of saving lives. This past October, Dr. Tromberg was elected to the National Academy of Medicine (NAM) for his contributions to the fields of biophotonics and biomedical optics, as well as his leadership in the biomedical engineering and imaging community.

Combination Therapy Shows Increased Effectiveness Against Brain Cancer

Additional Treatment Cuts off Tumor Cells’ Escape Route From Anti-Cancer Drug

MRI showing glioblastoma tumor in the brain

Despite the many therapies that scientists have created to fight cancer, treating the disease is often still a frustrating game of cat and mouse. Just when doctors think they have managed to defeat their wily opponent, it comes roaring back as strong as ever. A new IRP study suggests a two-pronged approach that relies in part on an existing anti-cancer drug could more effectively thwart a particularly deadly form of brain cancer.

NIH Mourns the Passing of Ji Ming Wang

Dr. Ji Ming Wang

The IRP community is profoundly saddened by the recent passing of Ji Ming Wang, M.D., Ph.D., Senior Investigator and Head of the Chemoattractant Receptor and Signal Section in the Cancer Innovation Laboratory at NIH's National Cancer Institute (NCI). He died unexpectedly on December 24, 2022.

Dr. Wang studied the role of chemoattractant receptors in infection, inflammation, immune responses and cancer progression for over 30 years. In 1998, Ji Ming was the first to identify a critical role for the receptors in mediating cancer cell metastasis to distant organs. His later work focused on leukocyte infiltration, a hallmark of inflammation and cancer progression.

Predicting Risks and Benefits for Lung Cancer Screening

IRP Researchers Refine Tools to Maximize the Benefit from Life-Saving Tests

patient getting a CT scan

Eleven years ago, IRP senior investigator Hormuzd Katki, Ph.D., had a bit of an eureka moment during a press event announcing the results of the National Lung Cancer Screening Trial, which demonstrated that annual screenings cut the risks of dying from lung cancer in heavy smokers by 20 percent.

“It struck me as I read the trial results that not only was this a very important trial, but that it was possible that different people will have different benefits from lung cancer screening,” Dr. Katki remembers. “Even within this group of very high-risk smokers who were part of the trial, you can identify some people who get much more benefit than other people, and that has implications for who should be offered this kind of screening.”

Michael Gottesman Reflects on Tenure Leading Intramural Research Program

Renowned Cancer Scientist Stepped Down After 29 Years in Position

Dr. Michael Gottesman

Dr. Michael Gottesman has been a member of the NIH community since 1976. He has held many positions throughout his tenure, including spending 29 years as the Deputy Director of Intramural Research (DDIR). He stepped down as DDIR this past year and has returned to focusing solely on being Chief of the Lab of Cell Biology at the National Cancer Institute (NCI). Dr. Gottesman recently participated in an interview with the NIH Office of Technology Transfer, excerpts of which we are re-posting here on the "I Am Intramural" blog. 

Simple Blood Test May Thwart a Complicated Cancer

Signs of Past Viral Exposure Predict Liver Cancer Risk

vials containing blood samples

The liver has a difficult but important job. It serves as the central processing plant for all the food, drinks, and drugs we take in, separating and breaking them down into usable nutrients and toxic wastes that need to be removed from the body. It’s no surprise, then, that diseases affecting the liver can have life-threatening consequences. In particular, infections like hepatitis B and C and liver damage caused by alcohol, drugs, or fatty liver disease can all lead to liver cancer. Unfortunately, even though the presence of these conditions are harbingers of possible liver cancer, the disease often passes unnoticed until it is at an advanced, less treatable stage.

IRP senior investigator Xin Wei Wang, Ph.D., and his NIH research team are developing ways to detect liver cancers much earlier, when existing treatments are much more likely to stop their growth. In honor of Liver Cancer Awareness Month this October, I talked to Dr. Wang about his research and the novel blood test his lab has developed to predict liver cancer risk.